Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 11Phase 3 5Phase 1/2 4Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 17Magnetic Resonance Spectroscopy 16Specimen Handling 13pembrolizumab 10Carboplatin 10Gemcitabine 9Paclitaxel 8Radiotherapy 7Radiation 7Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Pemetrexed 6Nivolumab 6Doxorubicin 6Surgical Procedures, Operative 5Radiotherapy, Intensity-Modulated 5Docetaxel 5Dexamethasone 5Biopsy 5atezolizumab 4Rituximab 4Immunoglobulin G 4Disulfides 4Bevacizumab 4Temozolomide 3Standard of Care 3Ramucirumab 3Drug Therapy 3Cyclophosphamide 3Cetuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Azacitidine × 30 days × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT07581002 2026-05-12

REVIVAL

AbbVie

Phase 2/3 Not yet recruiting
660 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡